Cannabis Wheaton Bolsters Team, Engages Investor Relations Firm



Cyber Security Law 网络安全法宣传视频系列001

Infection Control and Biosafety Products Market 2017-2021: Top Drivers and Forecasts by Technavio

LONDON–(BUSINESS WIRE)–Technavio market research analysts forecast the global infection control and biosafety products market to grow at a CAGR of more than 4% during the forecast period, according to their latest report.
The market study covers the present scenario and growth prospects of the global infection control and biosafety products market for 2017-2021. The report also lists infection control products and biosafety products as the two major product segments, of which infection control products accounted for close to 86% of the market share in 2016.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Technavio analysts highlight the following three market drivers that are contributing to the growth of the global infection control and biosafety products market:
Outbreak of life-threatening diseases
Growing disposable income and healthcare spending
Increasing level of customization for biosafety products
Outbreak of life-threatening diseases
In recent years, the outbreak of various diseases has affected several countries across the world. Diseases caused by bacteria like E. coli have been rampant in recent years. Lack of proper hygiene and sanitation is a major reason for the spread of diseases. A low-level of hygiene during hospital stay and patient care also creates a breeding ground for various microorganisms, such as viruses, bacteria, and spores that can lead to the spread of diseases.
Along with diseases such as Ebola virus disease, H1N1, and diseases caused by the E. coli bacteria, the Centers for Disease Control and Prevention (CDC) has also listed foodborne diseases as other disease outbreaks, which directly impact commercial consumers, such as hotels and restaurants, schools, and corporate offices, as well as domestic users.
“The increased number of healthcare facilities, healthcare research, and other related research has increased the consumption of infection control and biosafety products, which is a major market driver for the expansion of this market,” says Amber Chourasia, a lead analyst at Technavio for health and wellness research.
Growing disposable income and healthcare spending
The growth in per capita income has increased the disposable income and healthcare spending of individuals. Healthcare spending includes expenditure toward the prevention of diseases and the spending for their treatments.
“The increased healthcare spending of people towards better sanitation and cleanliness play a major role in preventing infections. The need to maintain proper hygiene increases the demand for infection control and biosafety products, which is driving the global market,” says Amber.
Increasing level of customization for biosafety products
Biosafety cabinets are enclosed, ventilated laboratory workspaces that are used for working safely with delicate or contaminated materials like pathogens that require a defined safety level. Biosafety cabinets find application in life sciences, clinical, pharmaceutical, and industrial laboratories.
Vendors also offer customization of products for application in various fields. This may include the materials used, the design of the storage platform or trays, air duct design, digital interface, illumination, and even temperature control. The choice of the type and size of the biosafety products is largely based on the application and the process for which they may be used.
With a wide range of cabinets to choose from based on material, size, function, design, and flexibility, end-users have the freedom to choose what best suits their application.
Browse Related Reports:
Global Physiotherapy Market 2017-2021
Aesthetic Market in US 2017-2021
Global Sports Supplement Market 2017-2021
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like outdoor gear, lab equipment, and agricultural equipment. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at


员工健康=企业绩效 整合型索迪斯健康管理实践
Cyber Security Law 网络安全法宣传视频《网络安全法》背景知识

Ring Main Unit (Gas, Air, Oil, and Solid Dielectric) Market 2017 by Type, Installation, Application and by Region – Global Forecast to 2022 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Ring Main Unit Market by Type (Gas, Air, Oil, and Solid Dielectric), Installation (Outdoor and Indoor), Application (Distribution Utilities, Industries, and Infrastructure & Transportation), and by Region – Global Forecast to 2022” report to their offering.
The ring main unit market is projected to reach USD 2.45 billion by 2022, at a CAGR of 8.35% from 2017 to 2022
Modernization of existing power infrastructure and capacity addition & enhancement plans for distribution networks have been boosting the demand for ring main units. In addition, end-user industries are deploying ring main units in secondary distribution networks for uninterrupted power supply. The high cost of ring main units as compared to conventional switchgear is a key factor restraining the growth of the ring main unit market.
Based on the type of ring main unit, the gas insulated segment is estimated to be the largest and fastest growing market from 2017 to 2022. The applications of gas insulated ring main unit include railway systems, wind power plants, power grids, underground installations, and mining applications. The gas insulated ring main unit is compact in size and has better functionality compared to other ring main units, thereby, driving the gas insulated ring main unit market.
The distribution utilities segment is the largest application market. Ring main units are extensively used by companies for secondary distribution networks and to protect their critical instruments. Moreover, this segment is expected to exhibit the highest CAGR from 2017 to 2022. The usage of ring main units for integrated distributed generation with the central grid is likely to drive the distribution utilities market.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Ring Main Unit Market, By Type
7 Ring Main Unit Market, By Installation
8 Ring Main Unit Market, By Application
9 Ring Main Unit Market, By Region
10 Competitive Landscape
11 Company Profiles
ABB Ltd.
C&S Electric Limited
Crompton Greaves Ltd
Eaton Corporation PLC.
Enetec Electric & Electronic Co., Ltd.
General Electric Company
LS Industrial Systems Co., Ltd.
Larsen & Toubro Limited

Lucy Electric
Schneider Electric Se
Siemens AG
For more information about this report visit



The Chicago Automobile Trade Association and USO of Illinois Partner for Fifth Year of Charitable "Barbecue for the Troops" Initiative




公告牌红毯风光好 张靓颖许魏洲很长脸

Aetna Board of Directors Declares Quarterly Cash Dividend

HARTFORD, Conn.–(BUSINESS WIRE)–The Board of Directors of Aetna (NYSE: AET) today declared a quarterly cash dividend of $0.50 per share on the company’s common stock. The dividend is payable on July 28, 2017, to shareholders of record at the close of business on July 13, 2017.

Declaration and payment of future dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.
About AetnaAetna is one of the nation’s leading diversified health care benefits companies, serving an estimated 44.9 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, and medical management capabilities, Medicaid health care management services, workers’ compensation administrative services and health information technology products and services. Aetna’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, see and learn about how Aetna is helping to build a healthier world. @AetnaNews


Cyber Security Law 网络安全法宣传视频《网络安全法》背景知识
中国国产航母烟囱冒出黑烟 疑进行主机点火试车(图)

Research and Markets – Global Serial Attached Storage (SAS) Solid-state Drive (SSD) Market 2017-2021: Key Vendors are Kingston Technology, Micron, Samsung, Toshiba & Western Digital


网络安全法动漫宣传片 002 国家网络安全的现状与重要性概述


金价有所回落 招金矿业下跌2%|招金矿业|下跌_新浪财经_新浪网
Cyber Security Law 网络安全法宣传视频《网络安全法》背景知识

Innovus Makes Strides Toward Goal of Tripling Revenue in 2017 —

REDONDO BEACH, CA–(Marketwired – May 19, 2017) –, a leading financial news and information portal offering free real time public filing alerts, recently published an article discussing Innovus Pharmaceuticals’ (OTCQB: INNV) recent financial results and the company’s goals going forward.
Closing in on Profitability
Innovus reported first quarter 2017 revenue of $2.2 million, which is a sharp increase from just $224,000 during the year ago period. On a sequential basis, the company’s revenue increased $500,000 — or 29% — despite the first quarter traditionally being its weakest. Historically, Innovus Pharmaceuticals quarter per quarter revenues show a very slow first quarter ($224K in 2016), followed by a significant increase in second quarter ($1M or close to 4x increase) and a peak in revenues in its third quarter ($1.9M close to 2x increase) and a slower fourth quarter ($1.7M).

On a linear flat growth basis, the company seems to be tracking to $8.8M in revenue for the year. But if we take into account their historical revenue patterns, the company may be able to reach and exceed its estimates for 2017. During a Q&A session on the earnings conference call, the company indicated that they expect to reach profitability upon hitting a $10 million revenue run rate, and considering past patterns (along with new product introductions and expanded distribution channels for existing products) that figure seems to be reachable this year. Gross margins improved to 79.8% from 46.7% a year ago, while cash used in operations decreased by $500,000 sequentially as the company moves closer to profitability.
“We have not only seen an increase in our net revenue from the most recent fourth quarter 2016 but our operating loss and cash used in operations has improved as we work to achieve our goal of profitability,” said Innovus Pharma President & CEO Bassam Damaj. “With the exciting news stemming from the commercial supply agreement we entered into with our new partner for FlutiCare™ in May 2017 and the recent completion of our registered public equity offering in March 2017, we believe we are well on our way to having the necessary resources to assist us in executing our goals of the expected launch of FlutiCare™ in the fourth quarter of 2017, the continued expansion of our product lines, and achieving profitability.”
Growing Innovative Product Lines
Innovus Pharmaceuticals continues to build its portfolio of consumer products for men and women’s health and respiratory diseases.
On May 1, the company announced the launch of ProstaGorx™ in the United States — a clinical strength, multi-response prostate supplement that is formulated to effectively maintain good prostate health and prevent future prostate issues. With multiple published clinical trials, the over-the-counter product has been shown to reduce prostate weight, regulate hormones, reduce nocturia, decrease PSA levels, and reduce the progression of prostate cancer.
“ProstaGorx is an excellent complement to our fast growing UriVarx™ product for bladder health and is the sixth product to date to be launched using our acquired Beyond Human sales and marketing platform,” said CEO Dr. Bassam Damaj in a recent press release. “We currently believe the product could generate an additional $2 million per year in revenue. This product launch moves us one step closer to achieving our 2017 revenue goals and profitability.”
The company’s other products already on the market include the Beyond Human Testosterone Booster; Beyond Human Human Growth Agent; Zestra® for female arousal; EjectDelay™ for premature ejaculation; Sensum+® for reduced penile sensitivity; Zestra Glide®; Vesele® for promoting sexual and cognitive health; Androferti® to support male reproductive health; Beyond Human Vision Formula; Beyond Human Lean Green Coffee; and UriVarx™ for bladder health.
Last year, these products generated $4.8 million in revenue, which is up from just $700,000 during FY 2015. The greatly increased gross margins signal growing pricing power and scalable operations. These gains were largely attributable to its Beyond Human marketing and distribution platform, which reaches between 20 million and 30 million customers on a monthly basis through print channels as well as over 2 million online subscribers to the platform’s more than 140 websites.
Expanding Footprint & Distribution
Innovus Pharmaceuticals has secured a growing number of patents, distribution agreements, and licensing arrangements around the world that protect its proprietary formulations and set the stage for future expansion into new markets.
Innovus announced a partnership agreement with West-Ward Pharmaceuticals International on May 9, 2017 that will enable Innovus to launch FlutiCare™ under West-Ward’s recently approved ANDA application No. 207957. Under the terms of the agreement, Innovus will be the first and only nationally branded over-the-counter product under the ANDA, and one of three nationally branded products with the same formulation. The company expects to generate upwards of $10 million in revenue in the first year from FlutiCare™, following the expected launch in the fourth quarter of 2017.
On May 15, the company announced a significant partnership for its approved product Zestra® in Europe with Densmore for the commercialization of the product in France and Belgium.
On May 18, the company announced that it filed a product license application in Canada for the commercialization of Vesele® as a natural health product to help improve the symptoms of sexual dysfunction. If accepted by Health Canada, the product will be available over-the-counter into 120 capsule bottles without a prescription and marketed through its Beyond Human sales platform that’s currently being setup in Canada and indicated that if the product is approved by Health Canada it expects to add an additional $0.5-$1M in revenues from the sale of the product in Canada.
The company made significant progress in FY 2016 in terms of expanding its reach, securing approval to commercialize Zestra® in the European Union, South Korea, and Lebanon. In addition, the company in-licensed Lertal® tablets for the United States and Canada under the brand name AllerVarx™ and launched Zestra® in the United States under its Beyond Human® sales and marketing platform to help grow the product to the next level.
On March 27, the company announced that it received a Notice of Intention to Grant form the European Patent Office to issue a European-wide patent for its Sensum+® product. Shortly after, the company received a CPNP notification from the European Union to commercialize its Zestra Glide® product in all 28 member countries, which brings the total number of approved-to-market products to three – the others being Zestra® and Sensum+®.
Please follow the link to read the full article:
Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:
在移动计算时代,移动学习Mobile Learning是重要的趋势。


脑瘫母亲做微商为儿攒学费 用鼻尖打字:一切为了儿子

北大博士后一人当官全家腐败 贪美色与十余女子私通




网络安全法动漫宣传片 002 国家网络安全的现状与重要性概述
幼童在游泳馆倒立溺水挣扎72秒 周围无人监护

La fundadora y directora ejecutiva de InGenesis se une a un grupo muy selecto de latinos con un título de doctorado

SAN ANTONIO–(BUSINESS WIRE)–La fundadora y directora ejecutiva de InGenesis, Veronica Muzquiz Edwards, se ha convertido oficialmente en la “Dra. Edwards” al completar esta semana su doctorado en administración de empresas. De esta manera, se une a un grupo muy selecto de académicos latinos con un doctorado. La Universidad de la Palabra Encarnada (University of the Incarnate Word, UIW) le entregó su diploma. Su investigación del Doctorado en Administración de Empresas (Doctorate of Business Administration, DBA) se enfocó en la preparación ante desastres y el liderazgo en casos de crisis.
Además de celebrar este “primer título” en la familia, la hija de la Dra. Edwards, Sydney, obtuvo un diploma en Licenciatura en Letras en derecho penal de la UIW el mismo día.
“Como alguien que desaprobó el primer grado, estoy orgullosa de haber completado mi doctorado. Esto sirve para demostrar que todo es posible”, afirmó la Dra. Edwards. “De más está decir que estoy sumamente orgullosa de mi hija y del ejemplo que es para todas las mujeres jóvenes”. Para tal fin, Edwards prometió que InGenesis continuará contribuyendo con la Asociación Hispana de Universidades (Hispanic Association of Colleges and Universities, HACU) y la Facultad de Medicina Osteopática de la UIW para incentivar a que cada vez más mujeres y personas de color busquen obtener títulos en estudios superiores.
Según los hallazgos más recientes del Centro Nacional de Estadísticas Educativas (National Center for Educational Statistics), el 7,2 % de los doctorados se otorgaron a hispanos entre 2014 y 2015. Si bien la cantidad de hispanos con un doctorado ha aumentado en la última década, la cantidad de hispanos que obtuvieron doctorados desde 1976 representa menos del 0,50 % de la población.
“Los logros de la Dra. Edwards y su hija deben hacer sentir orgullosa a su familia y su ejemplo inspirará a cualquier estudiante que aspire a metas similares”, expresó el presidente y director ejecutivo de la HACU, Antonio R. Flores. “La generosa contribución de InGenesis a nuestros programas de becas ayudará a otras personas a alcanzar sus propias metas de excelencia, en el mundo académico y en otros ámbitos”.
Luego de haber estado un año en el programa de doctorado, la Dra. Edwards postergó sus estudios poco después de un importante incendio en la sede anterior de InGenesis. Decidida a completar su título, volvió a las aulas. La Dra. Edwards es una ciudadana estadounidense de origen mexicano de la primera generación, que se incluye entre las primeras en participar en el programa inaugural de Doctorado en Administración de Empresas de la UIW y la primera en su familia en obtener un título superior académico.
La Dra. Edwards también fue nombrada recientemente por el prestigioso Programa de colegas ejecutivos de Baldridge (Baldridge Executive Fellows Program) del Instituto Nacional de Normas y Tecnología (National Institute of Standards and Technology, NIST) y pasará este próximo año analizando a las organizaciones de clase mundial y cómo los líderes sénior alcanzan la excelencia operativa y estratégica y promueven la innovación. Staffing Industry Analysts (SIA) ha reconocido a InGenesis como el mayor proveedor de personal diverso en atención médica, e incluyó a la Dra. Edwards en las listas prestigiosas de Staffing 100 y Global Power 100—Women in Staffing durante dos años consecutivos. InGenesis está certificada por la Comisión conjunta de servicios de dotación de personal de atención médica (Health Care Staffing Services, HCSS), un compromiso con la excelencia para brindar servicios de dotación de personal calificado y competente para respaldar la atención a los pacientes.
La Dra. Edwards fundó InGenesis en 1998, y fue creciendo hasta convertirse en una de las empresas estadounidenses más grandes de dotación de personal perteneciente a minorías y mujeres. InGenesis proporciona servicios de dotación de personal a decenas de sectores industriales, entre ellos atención médica, farmacia y biotecnología, servicios profesionales, servicios financieros, tecnología de la información y fabricación.
Acerca de InGenesis, Inc.
Fundada en 1998, InGenesis, Inc. es una de las empresas estadounidenses más grandes que ofrece soluciones de personal perteneciente a minorías y mujeres, y es reconocida por Staffing Industry Analysts (SIA) como la compañía proveedora de la más amplia diversidad en la industria de dotación de personal para atención médica. SIA también incluyó a la Dra. Edwards en las prestigiosas listas de Staffing 100 y Global Power 100—Women in Staffing durante dos años consecutivos. InGenesis está certificada por la Comisión conjunta de Servicios de dotación de personal de atención médica (Health Care Staffing Services, HCSS), un compromiso con la excelencia para brindar servicios de dotación de personal calificado y competente para respaldar la atención a los pacientes. Para obtener más información, visite
El texto original en el idioma fuente de este comunicado es la versión oficial autorizada. Las traducciones solo se suministran como adaptación y deben cotejarse con el texto en el idioma fuente, que es la única versión del texto que tendrá un efecto legal.



Hudson BLVD. Group To Launch First Multi-Brand Store




订单培训进企业 全年惠及超5000职工